High cure rate of invasive fungal infections in immunocompromised children using ambisome.
Ringdén
O
O
Division of Clinical Immunology, Karolinska Institute, Huddinge Hospital, Stockholm, Sweden.
Tollemar
J
J
Dahllöf
G
G
Tydén
G
G
D000293:Adolescent; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000276:immunology; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology; D002177:Candidiasis / Q000188:drug therapy / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D008081:Liposomes; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology; D008297:Male; D008271:Mycetoma / Q000188:drug therapy / Q000276:immunology; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology
D008081:Liposomes; C068538:liposomal amphotericin B; D000666:Amphotericin B